While existing biomarkers such as LDL-C, Lp(a), and ApoB are crucial, these markers, combined with other risk factors such as hypertension and tobacco use, still explain only a small proportion of CVD-related outcomes, including PAD, suggesting that additional unmeasured or unknown factors could improve early detection and prevention efforts. Here, APOB is linked to Hypertension.